Galmed Pharmaceutica (GLMD) Stock Price, Quote & News

Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 693 8448

Fax: 972 3 693 8447

Website: galmedpharma.com

Address:

16 Abba Hillel Road, Ramat Gan, Israel

CalculatedSwing Oct. 7 at 5:24 AM

$SPRB check $GLMD

0 · Reply

Lowlyme Oct. 7 at 4:52 AM

$GLMD Hope so. Best.

0 · Reply

Lowlyme Oct. 7 at 4:50 AM

$GLMD Ok. That was funny.

0 · Reply

JamoTries2Trade Oct. 7 at 3:30 AM

$IXHL Whattttttttt?!?!?!?!? $GLMD $NCNA Our day shall come… sooner than later. 🙏

2 · Reply

lookgoodplaygood22 Oct. 6 at 7:59 PM

$GLMD can do was $SPRB just did. This is the PR coming in THIS QUARTER for Aramchol PH3. Thus all the groundwork last few months with SEC for this announcement. Trust me. We can do 1000% in 1 day. Tell your mom, tell your dad. Tell your friends. If you like someone, tell them.

0 · Reply

oddlottrader Oct. 6 at 7:41 PM

$GLMD keep drinking class

0 · Reply

Trumpy14 Oct. 6 at 7:17 PM

$GLMD

0 · Reply

Putnik Oct. 6 at 7:05 PM

$GLMD

0 · Reply

VolcanicTrades Oct. 6 at 6:35 PM

$GLMD will probably end up like $SPRB congrats bulls

1 · Reply

getsometoday Oct. 6 at 6:25 PM

$GLMD power hour cmon

0 · Reply

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 25, 2025, 7:30 AM EDT - 6 weeks ago

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

May 27, 2025, 8:00 AM EDT - 4 months ago

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

May 22, 2025, 8:00 AM EDT - 4 months ago

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 5 months ago

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Apr 28, 2025, 8:00 AM EDT - 5 months ago

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Apr 17, 2025, 8:30 AM EDT - 6 months ago

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Apr 15, 2025, 8:30 AM EDT - 6 months ago

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Apr 10, 2025, 8:00 AM EDT - 6 months ago

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Apr 2, 2025, 4:10 PM EDT - 6 months ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 20, 2025, 8:55 AM EDT - 7 months ago

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Sep 25, 2024, 8:00 AM EDT - 1 year ago

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Apr 4, 2024, 5:06 PM EDT - 1 year ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Mar 15, 2024, 9:00 AM EDT - 1 year ago

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Nov 20, 2023, 4:32 PM EST - 2 years ago

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

Sep 22, 2023, 4:05 PM EDT - 2 years ago

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 14, 2023, 9:30 AM EDT - 2 years ago

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jul 10, 2023, 8:00 AM EDT - 2 years ago

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

May 9, 2023, 7:00 AM EDT - 2 years ago

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Mar 29, 2023, 5:00 PM EDT - 2 years ago

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

Feb 8, 2023, 8:00 AM EST - 2 years ago

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Dec 14, 2022, 5:00 PM EST - 3 years ago

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Aug 4, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Jul 7, 2022, 8:27 AM EDT - 3 years ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

May 17, 2022, 8:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

May 17, 2022, 7:30 AM EDT - 3 years ago

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

May 2, 2022, 1:56 PM EDT - 3 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2021 Results - Earnings Call Transcript

May 2, 2022, 7:00 AM EDT - 3 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Apr 28, 2022, 7:00 AM EDT - 3 years ago

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Jan 11, 2022, 7:30 AM EST - 4 years ago

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Jan 10, 2022, 9:14 AM EST - 4 years ago

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Jan 10, 2022, 7:30 AM EST - 4 years ago

Galmed announces positive results of Phase 1 study of Amilo-5MER

Nov 8, 2021, 3:24 PM EST - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2021 Results - Earnings Call Transcript

Nov 8, 2021, 7:30 AM EST - 4 years ago

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Nov 8, 2021, 7:00 AM EST - 4 years ago

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

Nov 1, 2021, 10:10 AM EDT - 4 years ago

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

Oct 11, 2021, 8:00 AM EDT - 4 years ago

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound

Aug 16, 2021, 8:00 AM EDT - 4 years ago

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study

Aug 9, 2021, 11:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2021 Results - Earnings Call Transcript

Aug 5, 2021, 7:00 AM EDT - 4 years ago

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

Aug 2, 2021, 9:26 AM EDT - 4 years ago

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial

Aug 2, 2021, 7:30 AM EDT - 4 years ago

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

Jul 29, 2021, 8:30 AM EDT - 4 years ago

Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5

May 13, 2021, 6:58 PM EDT - 4 years ago

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q1 2021 Results - Earnings Call Transcript

CalculatedSwing Oct. 7 at 5:24 AM

$SPRB check $GLMD

0 · Reply

Lowlyme Oct. 7 at 4:52 AM

$GLMD Hope so. Best.

0 · Reply

Lowlyme Oct. 7 at 4:50 AM

$GLMD Ok. That was funny.

0 · Reply

JamoTries2Trade Oct. 7 at 3:30 AM

$IXHL Whattttttttt?!?!?!?!? $GLMD $NCNA Our day shall come… sooner than later. 🙏

2 · Reply

lookgoodplaygood22 Oct. 6 at 7:59 PM

0 · Reply

oddlottrader Oct. 6 at 7:41 PM

$GLMD keep drinking class

0 · Reply

Trumpy14 Oct. 6 at 7:17 PM

$GLMD

0 · Reply

Putnik Oct. 6 at 7:05 PM

$GLMD

0 · Reply

VolcanicTrades Oct. 6 at 6:35 PM

$GLMD will probably end up like $SPRB congrats bulls

1 · Reply

getsometoday Oct. 6 at 6:25 PM

$GLMD power hour cmon

0 · Reply

lookgoodplaygood22 Oct. 6 at 4:53 PM

$GLMD 1 sixty. Next up 1.70.

0 · Reply

VolcanicTrades Oct. 6 at 3:39 PM

$GLMD scary October to be short

0 · Reply

getsometoday Oct. 6 at 3:36 PM

$GLMD

0 · Reply

whippster Oct. 6 at 3:29 PM

$GLMD

0 · Reply

CalculatedSwing Oct. 6 at 3:28 PM

$GLMD

0 · Reply

Lowlyme Oct. 6 at 3:13 PM

$GLMD You know what? I was gonna bow out, but then I got to thinking I'd be missing all those gifs.

0 · Reply

lookgoodplaygood22 Oct. 6 at 2:55 AM

$GIPR $GLMD $LAC $SOAR $ZONE GLMD should continue uptrend until Oct 28. PR drops before then it’ll be a gold mine. Low float scenario. Moves on very little volume.

0 · Reply

SurfTheTicker Oct. 6 at 1:33 AM

$LAC $10 $GIPR $12 $ZONE $6 $SOAR $4 $GLMD $2 🤝

0 · Reply

VolcanicTrades Oct. 5 at 11:26 PM

$GLMD

1 · Reply

lookgoodplaygood22 Oct. 5 at 10:02 PM

$GLMD

0 · Reply

Lowlyme Oct. 5 at 7:30 PM

$GLMD BTW I believe that Allen is the correct spelling of our CEO's name. Feel free to correct me if I'm mistaken. Best.

1 · Reply

Lowlyme Oct. 5 at 7:28 PM

$GLMD Add an update on OnKai stake.

0 · Reply

Market Cap	2.60M
Revenue (ttm)	0.00
Net Income (ttm)	-7.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	81,000
Avg Vol	158,662
Day's Range	N/A - N/A
Shares Out	1.65M
Stochastic %K	93%
Beta	0.50
Analysts	Hold
Price Target	$12.00